Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects

NCT04620213 is registered in ClinicalTrials.gov with Ocuphire Pharma, Inc. as lead sponsor.

NCT NCT04620213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04620213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects
Lead sponsor
Ocuphire Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 18, 2020
Completion date
March 15, 2021
Enrollment
185 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

dilation, mydriasis